Navigation Links
Affitech Acquires Pharmexa's Diabody Technology
Date:10/28/2008

OSLO, Norway, October 28 /PRNewswire/ -- Affitech AS, the human therapeutic antibody company, today announced that it had acquired the full rights to the innovative diabody technology originally owned by Pharmexa A/S, a leading Danish immunotherapeutic and vaccine company. Also known as bi-specific single chain antibodies, diabodies are recombinant antibody-like proteins whose unique attributes make them attractive candidates for a variety of therapeutic applications. The acquisition follows an exclusive license of the diabody IP that Affitech obtained in 2007 from Pharmexa to carry out certain non-clinical GLP compliant studies, as well as sub-licensing arrangements with third parties.

Affitech CEO Martin Welschof commented:

"This is a key strategic move for Affitech AS, since this diabody technology complements our existing antibody discovery platform perfectly. We are delighted to have this technology under our total ownership, which will benefit both our proprietary programs and our collaborations with pharma and biotech companies. In addition we will continue to seek actively sublicensing arrangements with third parties."

Editors notes

Affitech AS is a privately held human therapeutic antibody discovery and development company with headquarters and R&D facilities in Oslo, Norway and its US subsidiary in the San Francisco Bay Area. The Company's current disease focus is oncology and it utilizes two discrete but unique approaches for the discovery of fully human antibodies - (i) Molecule Based Antibody Discovery, and (ii) Cell Based Antibody Discovery. Molecule Based Antibody Discovery involves proprietary PhagemidScreeN and AffiScreeN(TM) technologies and uses validated targets for discovery purpose. Cell Based Antibody Discovery utilizes CBAS(TM) technology, which is a "reverse-screening" approach for discovering antibodies and their cognate targets from disease-specific cells. CBAS(TM) is also applicable to discovering antibodies against targets when present in their naturally folded forms on cell surface. Some of the Company's proprietary product candidates currently in research and development were generated by CBAS(TM). Affitech has concluded deals with commercial organizations such as Omeros, Roche, Peregrine, XOMA, NatImmune, Viventia, Dyax, Micromet, Pharmexa and others. Affitech offers collaborators a flexible business model and a competitive price structure with low royalty stacking. Further information at http://www.affitech.com.

Contacts for Affitech:

Affitech (Norway):

Dr. Martin Welschof,

Chief Executive Officer,

+47-22-95-87-58,

m.welschof@affitech.com .

Affitech (USA):

Dr. Rathin C. Das President,

+1-925-935-9803,

r.das@affitech.com .


'/>"/>
SOURCE Affitech AS
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
2. Affitech Appoints Dr. Keith McCullagh as Chairman
3. Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration
4. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
5. Neogen Acquires Kane Enterprises
6. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
7. Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek
8. United BioSource Acquires Interest in Leading Adaptive Design Technology Service Provider
9. NSF International Acquires David Begg Associates
10. United BioSource Acquires Caro Research, Leader in Simulation Modeling
11. Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2017)... ... May 20, 2017 , ... ... the lengthy trial and error process by finding the right antidepressant faster. ... strengthen the doctor-patient relationship through a personalized approach to treatment. , ...
(Date:5/18/2017)... ... May 18, 2017 , ... ... April 28, 2017 at the Prince Of Wales Private Hospital. The procedure was ... level C6-C7. The patient failed conservative treatments prior to undergoing surgery. , The ...
(Date:5/18/2017)... , ... May 17, 2017 , ... NDA Partners Chairman ... and former CEO of Eurofins Advantar Laboratories and President of Pharmaceutical Development Business Unit ... his position at Eurofins and Cardinal Health, he was former Chief Operating Officer at ...
(Date:5/18/2017)... ... 17, 2017 , ... USDM Life Sciences , the ... sciences and healthcare industries, is honored that Jay Crowley was selected ... Brussels, Belgium. , Crowley played a crucial role in the development of the ...
Breaking Biology Technology:
(Date:3/22/2017)... March 21, 2017 Optimove , ... by retailers such as 1-800-Flowers and AdoreMe, today ... Recommendations and Replenishment. Using Optimove,s machine learning algorithms, ... product and replenishment recommendations to their customers based ... predictions of customer intent drawn from a complex ...
(Date:3/20/2017)... -- At this year,s CeBIT Chancellor Dr. Angela Merkel ... Chancellor came to the DERMALOG stand together with the Japanese Prime Minster ... country. At the largest German biometrics company the two government leaders could ... recognition as well as DERMALOGĀ“s multi-biometrics system.   ... ...
(Date:3/16/2017)... HANOVER, Germany , March 16, 2017 CeBIT 2017 - Against ... Continue Reading ... Used combined in one project, multi-biometric solutions ... ... Identification Systems) ...
Breaking Biology News(10 mins):